A study in healthy subjects to assess the pharmacokinetics of savolitinib when administered alone and in combination with rifampicin

Study identifier:D5084C00003

ClinicalTrials.gov identifier:NCT04118842

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-label, 3-period Fixed-sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib when Administered Alone and in Combination with Rifampicin

Medical condition

Solid Tumors

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Savolitinib, Rifampicin

Sex

Male

Actual Enrollment

20

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 17 Oct 2019
Primary Completion Date: 26 Feb 2020
Study Completion Date: 26 Feb 2020

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Basic Science

Verification:

Verified 01 Sept 2020 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria